U.S., Dec. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07294677) titled 'Trial to Test Safety of Adding Capivasertib to a Standard Leukemia Treatment Regimen' on Dec. 12.
Brief Summary: This is a 3-part study to assess the safety of adding capivasertib to a standard of care treatment regimen consisting of venetoclax and low-intensity chemotherapy. This chemotherapy regimen called mini-hyperCVD consists of the chemotherapy drugs, cyclophosphamide, vincristine, dexamethasone; (part A) alternating with high-dose methotrexate and cytarabine (part B) administered approximately every 28 days.
In the first part of the study (Cohort 1), the study seeks to determine the recommended dose of capivasertib that can ...